Alzheimer’s Disease Assessment Scale (ADAS)

Abstract

The Alzheimer’s Disease Assessment Scale (ADAS) is one of the most widely used psychometric tools for assessing the severity of cognitive impairment and behavioral disturbances associated with Alzheimer’s disease (AD). Developed primarily for use in clinical drug trials, the ADAS provides a standardized method for quantifying changes in core symptoms over time. The scale is typically divided into two main sections: the Cognitive Subscale (ADAS-Cog), which is the most frequently utilized component, and the Non-Cognitive Behavior section, which assesses mood, functional, and psychotic symptoms. Higher scores indicate greater severity of impairment.

Keywords

Alzheimer’s Disease Assessment Scale, ADAS, ADAS-Cog, cognitive impairment, dementia, rating scale, clinical trials, psychometrics, geriatric assessment, Mohs, Rosen.

Authors

W. G. Rosen, R. C. Mohs, K. L. Davis

Purpose

The primary purpose of the Alzheimer’s Disease Assessment Scale (ADAS) is to measure the severity of cognitive and non-cognitive symptoms in patients diagnosed with Alzheimer’s disease, allowing for the quantitative tracking of disease progression or the efficacy of anti-dementia treatments in clinical trials. The scale was specifically designed to capture subtle changes in cognitive function that are characteristic of AD, making it sensitive to treatment effects. While the ADAS was originally developed in 1983, variations, such as the ADAS-Cog (focusing solely on cognitive items) and extended versions like the ADAS-Cog-Plus, have evolved to improve responsiveness, particularly in patients with Mild Cognitive Impairment (MCI).

Construct

The ADAS measures a multifaceted construct comprising both cognitive and non-cognitive behavioral deficits commonly observed in patients with AD. The scale is structured to assess several key domains:

• Cognitive Function: This subscale (ADAS-Cog) focuses on core deficits of AD, including memory (recall and recognition), language abilities (spoken language, comprehension, naming, word-finding), orientation (time, place, person), and praxis (constructional and ideational).
• Non-Cognitive Behavior: This section assesses behavioral and affective disturbances, such as mood (depression, tearfulness), psychotic features (delusions, hallucinations), and motor activity (pacing, tremors), which are crucial indicators of overall disease burden and caregiver stress.

The scoring methodology is based on severity, where a higher score reflects greater impairment. For most items, a score of 0 signifies no impairment, while a rating up to 5 (or higher for specific memory tasks) reflects severe impairment or high frequency of a particular behavior.

Validity

The validity of the ADAS, particularly the ADAS-Cog subscale, is well-established, demonstrating strong concurrent and criterion validity in differentiating patients with AD from healthy controls and in correlating with other measures of global cognitive decline, such as the Mini-Mental State Examination (MMSE). Early studies by Mohs and colleagues established the scale’s ability to track changes over time, reinforcing its utility as a primary outcome measure in pharmacological trials.

Furthermore, research has confirmed the scale’s construct validity, showing that the cognitive items successfully cluster into factors representing key domains of AD pathology, such as memory and language. The development of neuropathologically validated scales (Mohs et al., 1983) further strengthened the instrument’s foundation, ensuring that the measured deficits align with the underlying neurobiology of the disease. The scale’s responsiveness to change over short periods is crucial for its application in clinical research.

Reliability

The reliability of the ADAS has been extensively documented, demonstrating high inter-rater reliability and internal consistency, especially for the cognitive subscale. Studies conducted in multicenter clinical trials have confirmed that the ADAS is consistent across various clinical settings and raters (Weyer et al., 1997). This strong inter-rater reliability is essential for maintaining standardization in large-scale clinical trials where multiple sites and assessors are involved.

While the cognitive subscale (ADAS-Cog) generally exhibits superior internal consistency, the non-cognitive behavioral items often show lower internal consistency due to the fluctuating nature of behavioral symptoms in dementia. Despite this variability, the ADAS remains the gold standard for measuring cognitive change in AD research due to its robust psychometric properties related to the core cognitive domains.

Factor Analysis

Factor-analytic studies of the ADAS have consistently supported its multidimensional structure. Research, such as that by Talwalker et al. (1996), identified cardinal features of cognitive dysfunction that load onto distinct factors. Typically, the ADAS-Cog items resolve into factors related to: 1) Memory (e.g., word recall and recognition), 2) Language (e.g., spoken language ability and naming), and 3) Praxis/Orientation (e.g., following commands, constructions, and orientation). This factor structure confirms that the scale effectively taps into the diverse cognitive deficits that define Alzheimer’s pathology.

Instrument

Test Type: Performance-based interview and clinical rating scale

Format: Examiner-administered tasks and observation/interview-based ratings

Language Available: English (Original), widely translated and validated into numerous languages for international clinical trials.

Population Group: Geriatric and adult populations

Age Group: Typically 50 years and older

Population Details: Individuals diagnosed with Alzheimer’s disease (AD) or Mild Cognitive Impairment (MCI), primarily used in clinical settings to monitor disease progression.

Test Methodology: The scale involves the administration of specific cognitive tasks (e.g., word lists, naming pictures, copying geometric forms) followed by clinical rating of the patient’s performance and observation of non-cognitive behaviors.

Keywords

Dementia assessment, neurocognitive scale, clinical psychometrics, AD progression, rating instrument, ADAS-Cog-Plus, Alzheimer’s clinical trial endpoint, cognitive decline.

Authors

Author ORCID Identifier: N/A (Information not available in source content)

Affiliation Email addresses: N/A (Information not available in source content)

Correspondence Address: N/A (Information not available in source content)

Permissions & Fee and Test Year

The ADAS was initially published in 1983/1984 by Rosen, Mohs, and Davis. While the original scale is widely recognized and used in academic settings, its use in commercial clinical trials often requires licensing or permission, particularly when standardized training and materials provided by specialized organizations (like the Alzheimer’s Disease Cooperative Study, ADCS) are utilized.

The original PDF of the instrument can be downloaded here: www.a4ebm.org/sites/default/files/Measuring%20Health.pdf

Reference’s

• Mohs, R.C & Cohen L (1988). Alzheimer’s Disease Assessment Scale (ADAS). Psychopharmacology Bulletin, 24: 627-628.
• Mohs, R.C., Rosen, W.G., Greenwald, B.S, et al. (1983). Neuropathologically validated scales for Alzheimer’s disease. In: Crook T, Ferris S, Bartus R, eds. Assessment in geriatric psychopharmacology. New Canaan, Connecticut: Mark Powley, 37–45.
• Mohs, Richard C.; Knopman, David; Petersen, Ronald C.; Ferris, Steven H.; Ernesto, Chris; Grundman, Michael; Sano, Mary; Bieliauskas, Linas; Geldmacher, David; Clark, Chris; Thai, Leon J. (1997). Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer’s Disease Assessment Scale That Broaden Its Scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease & Associative Disorders. 11(Suppl 2):S13–21.
• McDowell, Ian. (2006). Measuring Health: A Guide to Rating Scales and Questionnaires, Third Edition. OXFORD UNIVERSITY PRESS.
• Rosen, W.G, Mohs, R.C & Davis, K.L. (1984). A new rating scale for Alzheimer’s disease. American Journal of Psychiatry, 141(11): 1356-1364.
• Rosen, W.G., Mohs, R.C., Davis, K.L. (1986). Longitudinal changes: cognitive, behavioral, and affective patterns in Alzheimer’s disease. In: Poon LW, Crook T, Davis KL, et al., eds. Handbook for clinical memory assessment of older adults. Washington, DC: American Psychological Association, 294–301.
• Skinner, Jeannine., Carvalho, Janessa O., Potter, Guy G., et al. (2012). The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav, 6(4):489-501.
• Talwalker, S., Overall, J. E., Srirama, M. K., & Gracon, S. I. (1996). Cardinal features of cognitive dysfunction in Alzheimer’s disease: a factor-analytic study of the Alzheimer’s Disease Assessment Scale. Journal of Geriatric Psychiatry and Neurology, 9, 1, 39-46.
• Weyer, G., Erzigkeit, H., Kanowski, S, et al. (1997). Alzheimer’s Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr, 9:123–138.

Items of the Alzheimer’s Disease Assessment Scale (ADAS)

Cognitive Behavior

1. Spoken language ability (0–5)
2. Comprehension of spoken language (0–5)
3. Recall of test instructions (0–5)
4. Word-finding difficulty (0–5)
5. Following commands (0–5)
6. Naming objects and fingers (0–5)
7. Constructions—copying forms (0–5)
8. Ideational praxis (0–5)
9. Orientation to time, place, and person (0–8)
10. Word recall memory test (0–10)
11. Word recognition memory test (0–12)

Noncognitive behavior

1. Tearful appearance (0–5)
2. Appears or reports depressed mood (0–5)
3. Concentration, distractibility (0–5)
4. Lack of cooperation in testing (0–5)
5. Delusions (0–5)
6. Hallucinations (0–5)
7. Pacing (0–5)
8. Increased motor activity (0–5)
9. Tremors (0–5)
10. Increased or decreased appetite (0–5)

For each severity scale, 0 signifies no impairment on a task or the absence of a particular behavior. A rating of 5 reflects severe impairment or high frequency of a behavior.